|Manufacturer:||Bristol Myers Squibb, NZ manufactures Capoten.|
|Uses:||The uses of Capoten include:|
Capoten is indicated for the treatment of hypertension in adult and paediatric patients. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of Capoten and thiazides are additive.
Capoten is indicated for the treatment of patients with heart failure. In such patients it is recommended that Capoten be administered with a diuretic.
Capoten is indicated in clinically stable patients with asymptomatic and symptomatic left ventricular dysfunction following myocardial infarction to improve survival and reduce the risk of recurrent myocardial infarction or hospitalisation for heart failure.
Capoten is indicated for the treatment of diabetic nephropathy in Type 1 diabetes with or without hypertension. In these patients Capoten prevents the progression of renal disease and reduces associated clinical sequelae (dialysis, renal transplantation and death).